Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

This trial is testing a treatment called TIL therapy (tumor-infiltrating lymphocyte therapy), where immune cells are taken from a patient's own melanoma tumor, grown in large numbers in the lab, and then infused back into the patient to help fight the cancer, in patients with uveal melanoma (a rare eye melanoma) that has spread. **You may be eligible if...** - You are between 18 and 75 years old - You have metastatic uveal melanoma (the cancer has spread from the eye to other organs) with measurable tumors - You are already enrolled in the companion cell preparation study at the same institution and have viable TIL cultures available - You are in good overall health (ECOG 0–1) - You have a life expectancy of more than 3 months - You have satisfactory blood counts, kidney, and liver function - You are negative for HIV, hepatitis B, and hepatitis C - You agree to use birth control during and for 4 months after treatment **You may NOT be eligible if...** - You have more than 3 brain metastases or brain tumors larger than 1 cm - You are HIV positive - You are pregnant - You have active hepatitis B or C - Your blood counts or organ function are below required thresholds Talk to your doctor to see if this trial is right for you.